BioNTech SE (BNTX)
$89.01-7.13%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $22.5B
- Beta
- 1.25
- P/E (TTM)
- -11.82
- Short % float
- 0.99%
- Days to cover
- 3.1
- SI change
- +7.5%
- 1W
- -7.02%
- 1M
- -9.96%
- vs SPY 1W
- -6.88%
- vs SPY 1M
- -12.47%
Industry peers
FMP comparable companies · ranked by market cap
- GMABBUYGenmab A/S$22.9BBULLQ 21$37.37-2.14%
- INCYSELLIncyte Corporation$22.6BBEARQ 13$111.36-2.46%
- IBRXBUYImmunityBio, Inc.$10.6BRECOVERYQ 8$10.12-3.16%
- TGTXSELLTG Therapeutics, Inc.$8.5BBEARQ 11$55.27-1.68%
- IOVABUYIovance Biotherapeutics, Inc.$6.5BRECOVERYQ 9$14.56-0.41%
- XNCRSELLXencor, Inc.$1.9BRECOVERYQ 15$25.04-6.07%
- IMCRSELLImmunocore Holdings plc$1.5BBEARQ 1$29.04-4.20%
- IMTXSELLImmatics N.V.$967MCRISISQ 5$7.21-5.27%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on BNTX?
- LOPJLB’s latest quantitative signal on BioNTech SE (BNTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is BNTX in?
- BioNTech SE (BNTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does BioNTech SE (BNTX) do?
- BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a fo…